RT Journal Article
SR Electronic
T1 Effectiveness of a chatbot in improving the mental wellbeing of health workers in Malawi during the COVID-19 pandemic: A randomized, controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.24.23284959
DO 10.1101/2023.01.24.23284959
A1 Eckhard F. Kleinau
A1 Tilinao Lamba
A1 Wanda Jaskiewicz
A1 Katy Gorentz
A1 Ines Hungerbuehler
A1 Donya Rahimi
A1 Demoubly Kokota
A1 Limbika Maliwichi
A1 Edister S. Jamu
A1 Alex Zumazuma
A1 Mariana Negrão
A1 Raphael Mota
A1 Yasmine Khouri
A1 Michael Kapps
YR 2023
UL http://medrxiv.org/content/early/2023/02/02/2023.01.24.23284959.abstract
AB We conducted a randomized, controlled trial (RCT) to investigate our hypothesis that the interactive chatbot, Vitalk, is more effective in improving mental wellbeing and resilience outcomes of health workers in Malawi than the passive use of Internet resources.For our 2-arm, 8-week, parallel RCT (ISRCTN Registry: trial ID ISRCTN16378480), we recruited participants from 8 professional cadres from public and private healthcare facilities. The treatment arm used Vitalk; the control arm received links to Internet resources. The research team was blinded to the assignment. Of 1,584 participants randomly assigned to the treatment and control arms, 215 participants in the treatment and 296 in the control group completed baseline and endline anxiety assessments. Six assessments provided outcome measures for: anxiety (GAD-7); depression (PHQ-9); burnout (OLBI); loneliness (ULCA); resilience (RS-14); and resilience-building activities. We analyzed effectiveness using mixed-effects linear models, effect size estimates, and reliable change in risk levels.Results support our hypothesis. Difference-in-differences estimators showed that Vitalk reduced: depression (−0.68 [95% CI -1.15 to -0.21]); anxiety (−0.44 [95% CI -0.88 to 0.01]); and burnout (−0.58 [95% CI -1.32 to 0.15]). Changes in resilience (1.47 [95% CI 0.05 to 2.88]) and resilience-building activities (1.22 [95% CI 0.56 to 1.87]) were significantly greater in the treatment group. Our RCT produced a medium effect size for the treatment and a small effect size for the control group.This is the first RCT of a mental health app for healthcare workers during the COVID-19 pandemic in Southern Africa combining multiple mental wellbeing outcomes, and measuring resilience and resilience-building activities. A significant number of participants could have benefited from mental health support (1 in 8 reported anxiety and depression; 3 in 4 suffered burnout; and 1 in 4 had low resilience). Such help is not readily available in Malawi. Vitalk has the potential to fill this gap.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN16378480Clinical Protocols https://www.isrctn.com/editorial/retrieveFile/1326fa36-af4d-4eb3-ad16-27f20f652ce1/41650 Funding StatementFinancial support for this RCT was provided by the United States Agency for International Development under the Cooperative Agreement No. AID-OAA-A-15-00046. The funders had no involvement in the analysis or in the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Malawi Research Ethics Committee (UNIMAREC) gave ethical approval for this work. Ethics committee/IRB of University Research Co. (URC) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced will be available online after acceptance of publication at https://data.usaid.gov/